Ocuphire Pharma Stock Is Trading Higher After Nyxol Aces Late-Stage Study

Ocuphire Pharma Inc (NASDAQ: OCUP) stock is soaring in the premarket in reaction to positive data from MIRA-2 Phase 3 trial evaluating Nyxol. Nyxol is an eye drop formulation of phentolamine mesylate designed to reverse pharmacologically induced mydriasis (dilation of pupil for eye exams).

• The study met its primary endpoint, with 49% of subjects treated with Nyxol returning to less than 0.2 mm of their baseline pupil diameter at 90 minutes compared to 7% of subjects treated with placebo.

• A higher number of Nyxol treated subjects returned to baseline pupil diameter at 60 minutes compared to placebo.

• Nyxol treated subjects had mean pupil diameters that were 1 to 2.5 mm smaller than placebo-treated subjects at all time points from 1 to 6 hours post-dosing.

• Nyxol treated subjects returned to baseline pupil diameter more quickly than placebo-treated subjects.

• The treatment was well-tolerated and demonstrated a favorable safety profile.

• The company plans to start a second Phase 3 trial in the second half of this year. FDA marketing application is expected to be submitted in early 2023.

• Full results from the MIRA-2 Phase 3 trial will be presented at an upcoming industry conference - 2021 ASCRS Annual Meeting July 23–27 in Las Vegas, Nevada.

• Price Action: OCUP gained 88.7% at $14.99 in premarket trading on the last check Monday.

See more from Benzinga

• Click here for options trades from Benzinga

• Inhibrx's INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study

• Cyclacel Pharmaceuticals Presses Capital Raise Button

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.